newsfilter
← Latest News
ClinicalTrials.gov·

A Phase Ib/II Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma - NCT05521802

[phase Ib] Incidence and severity of Adverse Events, [phase II] Overall response rate (ORR) at 3 months after C-CAR088 infusion, Overall response rate (ORR), (and 15 more...)